Van Cleef Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $542K | Hold |
8,937
| – | – | 0.06% | 85 |
|
|
2025
Q4 | $482K | Sell |
8,937
-3,311
| -27% | -$159K | 0.05% | 89 |
|
|
2025
Q3 | $552K | Buy |
12,248
+2
| +0% | +$93 | 0.06% | 82 |
|
|
2025
Q2 | $567K | Sell |
12,246
-1,439
| -11% | -$70.6K | 0.06% | 78 |
|
|
2025
Q1 | $835K | Sell |
13,685
-987
| -7% | -$57.5K | 0.09% | 59 |
|
|
2024
Q4 | $830K | Buy |
14,672
+2
| +0% | +$112 | 0.09% | 63 |
|
|
2024
Q3 | $759K | Sell |
14,670
-1,759
| -11% | -$82.5K | 0.08% | 68 |
|
|
2024
Q2 | $682K | Sell |
16,429
-799
| -5% | -$35.8K | 0.09% | 65 |
|
|
2024
Q1 | $934K | Sell |
17,228
-348
| -2% | -$17.7K | 0.12% | 61 |
|
|
2023
Q4 | $902K | Buy |
17,576
+3,299
| +23% | +$173K | 0.13% | 58 |
|
|
2023
Q3 | $829K | Sell |
14,277
-1,529
| -10% | -$93.7K | 0.13% | 58 |
|
|
2023
Q2 | $1.01M | Sell |
15,806
-1,777
| -10% | -$119K | 0.16% | 56 |
|
|
2023
Q1 | $1.22M | Sell |
17,583
-165
| -0.9% | -$11.6K | 0.19% | 54 |
|
|
2022
Q4 | $1.28M | Buy |
17,748
+1,276
| +8% | +$96.2K | 0.21% | 52 |
|
|
2022
Q3 | $1.17M | Buy |
16,472
+16
| +0.1% | +$1.16K | 0.23% | 52 |
|
|
2022
Q2 | $1.27M | Sell |
16,456
-424
| -3% | -$32.3K | 0.21% | 52 |
|
|
2022
Q1 | $1.23M | Sell |
16,880
-299
| -2% | -$20.1K | 0.18% | 55 |
|
|
2021
Q4 | $1.07M | Buy |
17,179
+201
| +1% | +$11.8K | 0.15% | 59 |
|
|
2021
Q3 | $1M | Sell |
16,978
-639
| -4% | -$42.1K | 0.15% | 59 |
|
|
2021
Q2 | $1.18M | Sell |
17,617
-1,274
| -7% | -$83.1K | 0.17% | 56 |
|
|
2021
Q1 | $1.19M | Sell |
18,891
-1,582
| -8% | -$98.4K | 0.19% | 53 |
|
|
2020
Q4 | $1.27M | Sell |
20,473
-1,149
| -5% | -$70.7K | 0.21% | 51 |
|
|
2020
Q3 | $1.3M | Buy |
21,622
+451
| +2% | +$27.1K | 0.24% | 48 |
|
|
2020
Q2 | $1.25M | Sell |
21,171
-175
| -0.8% | -$10.5K | 0.25% | 50 |
|
|
2020
Q1 | $1.19M | Sell |
21,346
-369
| -2% | -$22.6K | 0.29% | 47 |
|
|
2019
Q4 | $1.39M | Buy |
21,715
+6,825
| +46% | +$391K | 0.28% | 50 |
|
|
2019
Q3 | $755K | Sell |
14,890
-200
| -1% | -$9.4K | 0.17% | 67 |
|
|
2019
Q2 | $684K | Sell |
15,090
-300
| -2% | -$14K | 0.15% | 69 |
|
|
2019
Q1 | $734K | Buy |
15,390
+1,000
| +7% | +$49.8K | 0.17% | 66 |
|
|
2018
Q4 | $748K | Sell |
14,390
-380
| -3% | -$20.4K | 0.2% | 62 |
|
|
2018
Q3 | $917K | Sell |
14,770
-640
| -4% | -$38K | 0.2% | 55 |
|
|
2018
Q2 | $853K | Buy |
15,410
+1,610
| +12% | +$87K | 0.2% | 57 |
|
|
2018
Q1 | $873K | Sell |
13,800
-50
| -0.4% | -$3.22K | 0.22% | 58 |
|
|
2017
Q4 | $849K | Hold |
13,850
| – | – | 0.21% | 62 |
|
|
2017
Q3 | $883K | Sell |
13,850
-1,100
| -7% | -$64.2K | 0.24% | 55 |
|
|
2017
Q2 | $833K | Hold |
14,950
| – | – | 0.24% | 58 |
|
|
2017
Q1 | $813K | Sell |
14,950
-200
| -1% | -$11K | 0.25% | 58 |
|
|
2016
Q4 | $885K | Sell |
15,150
-101
| -0.7% | -$5.52K | 0.28% | 55 |
|
|
2016
Q3 | $822K | Hold |
15,251
| – | – | 0.27% | 52 |
|
|
2016
Q2 | $1.12M | Sell |
15,251
-899
| -6% | -$63.5K | 0.39% | 47 |
|
|
2016
Q1 | $1.03M | Sell |
16,150
-79
| -0.5% | -$4.98K | 0.37% | 49 |
|
|
2015
Q4 | $1.12M | Sell |
16,229
-99
| -0.6% | -$6.54K | 0.41% | 46 |
|
|
2015
Q3 | $967K | Buy |
16,328
+1,901
| +13% | +$121K | 0.38% | 47 |
|
|
2015
Q2 | $960K | Sell |
14,427
-599
| -4% | -$39.5K | 0.36% | 48 |
|
|
2015
Q1 | $969K | Sell |
15,026
-500
| -3% | -$31.3K | 0.36% | 49 |
|
|
2014
Q4 | $916K | Buy |
15,526
+2,511
| +19% | +$142K | 0.34% | 50 |
|
|
2014
Q3 | $666K | Buy |
13,015
+2
| +0% | +$100 | 0.27% | 53 |
|
|
2014
Q2 | $631K | Buy |
13,013
+4,328
| +50% | +$213K | 0.26% | 54 |
|
|
2014
Q1 | $451K | Sell |
8,685
-99
| -1% | -$5.27K | 0.2% | 64 |
|
|
2013
Q4 | $467K | Hold |
8,784
| – | – | 0.21% | 62 |
|
|
2013
Q3 | $407K | Buy |
8,784
+1
| +0% | +$44 | 0.2% | 64 |
|
|
2013
Q2 | $392K | Buy |
+8,783
| New | +$381K | 0.21% | 64 |
|
Other funds holding BMY
VCM
VPM
Van Cleef Asset Management's BMY Position: Q1 2026 in Review
Van Cleef Asset Management held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 8,937 shares worth $542K. The position accounts for 0.06% of the portfolio, ranked #85.
Van Cleef Asset Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.39M in Q4 2019. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Van Cleef Asset Management held 8,937 shares of Bristol-Myers Squibb worth $542K as of Q1 2026.
- Van Cleef Asset Management left its Bristol-Myers Squibb share count unchanged in Q1 2026.
- Bristol-Myers Squibb made up 0.06% of Van Cleef Asset Management's portfolio in Q1 2026, its #85 holding.
- Van Cleef Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- Van Cleef Asset Management's Bristol-Myers Squibb position peaked at $1.39M in Q4 2019.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Van Cleef Asset Management's 13F filing for Q1 2026, filed 1 May 2026.